Skip to main content
Top
Literature
1.
go back to reference Martin-Loeches I, Antonelli M, Cuenca-Estrella M et al (2019) ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med 45:789–805CrossRef Martin-Loeches I, Antonelli M, Cuenca-Estrella M et al (2019) ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med 45:789–805CrossRef
2.
go back to reference Dreyfuss D, Ricard J-D, Gaudry S (2013) Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications. Am J Respir Crit Care Med 187:661–663CrossRef Dreyfuss D, Ricard J-D, Gaudry S (2013) Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications. Am J Respir Crit Care Med 187:661–663CrossRef
3.
go back to reference Limper AH, Knox KS, Sarosi GA et al (2011) An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96–128CrossRef Limper AH, Knox KS, Sarosi GA et al (2011) An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96–128CrossRef
Metadata
Title
Conventional amphotericin B should remain in the armamentarium as a cheap and efficient waiting solution
Authors
Damien Roux
Stéphane Gaudry
Didier Dreyfuss
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 3/2020
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-019-05782-z

Other articles of this Issue 3/2020

Intensive Care Medicine 3/2020 Go to the issue